ЛИТЕРАТУРА
Белоусов Ю.Б., Чикина Е.С., Медников О.И. Фармакоэкономические аспекты лечения деменции в РФ. РМЖ, т.13, № 20, 2005.
Белоусов Ю.Б., и др. Сравнительная фармакоэкономическая оценка современных препаратов для терапии болезни Альцгеймера, Отчет РГМУ, Российского общества клинических исследвоаний, ООО «Центр фармакоэкономических исследований», 2007
Гаврилова С.И. и др. Эффективность терапии Экселоном при болезни Альцгеймера с сопутствующей церебрально-сосудистой патологией. 7 Международный конгресс по болезни Альцгеймера и болезни Паркинсона, Сорренто, 9-13 мая 2005г.
Гаврилова С.И. Фармакотерпия болезни Альцгеймера. Москва, издательство Пульс 2007, 359с.
Преображенская И.С., Н.Н. Яхно. Холинергическая терапия нейродегенеративных деменций. Справочник практического врача. №3, 2005
Численность населения Российской Федерации по полу и возрасту на 1 января 2006 года. Статистический бюллетень. Росстат. – М., 2006
Alzheimer’s Disease international (ADI). Available at http://www.alz.co.uk
Amici S., Lanari A., Romani R., et al. Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmine. Mech Ageing Dev 2001; 122: 2057-62.
Anand R., Messina J., Hartman R. Dose-response effect of rivastigmine in the treatment of Alzheimer’s disease. Int J Geriatr Psychopharmacol 2000; 2: 68-72.
Aguglia E., Onor M.L., Saina M., Maso E. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting. Curr Med Res Opin 2004; 20: 1747-1752.
Auriacombe S., Pere J.J., Loria-Kanza Y., Vellas B. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease who failed to benefit from treatment with donepezil. Curr Med Res Opin 2002; 18: 129-38.
Bartorelli, L.,Giraldi, C. et al. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease, Curr Med Res Opin, 2005: 1809-18
Bell C.M., Araki S.S., Neumann P.J. The association between caregiver burden and caregiver health-related quality of life in Alzheimer’s disease. Alzheimer Dis Assoc Disord 2001: 15: 129-36
Birks J, Grimley J Evans, Iakovidou V. Tsolaki M. Rivastigmine for Alzheimer's disease. The Cochrane Collaboration, 2000
Bullock R, Touchon J, Bergman H, Gambina G, He Yu, Rapatz G, Nagel N.,Lane R. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer’s disease over a 2-year period. Current Medical Research And Opinion. Vol. 21, No. 8, 2005, 1317–1327.
Bullock R., Connolly C. Switching cholinesterase inhibitor therapy in Alzheimer’s disease – donepezil to rivastigmine, is it worth it. Int J Geriatric Psychiatry 2002; 17: 288-9.
Bullock R., Moulias R., Steinwachs K.-C., Cicin-Sain A.G., Spiegel R. Effects of rivastigmine on behavioural symptoms in nursing home patients with Alzheimer’s disease. Int Psychogeriatr 2001; 13 (Suppl.2): 242 (Abstract P-248).
Bullock, R. Dengiz, A. Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years, Int J Clin Pract, 2005: 817-22
Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Psychopharmacol. 1998;2:55-65
Cras P. Differential diagnosis in dementia. Acta neurol Beig 1998: 98: 186-9
Cummings JL, Anand R, Koumaras B, Hartman R. Behavioral benefits in Alzheimer’s disease patients residing in a nursing home following 52 weeks of rivastigmine treatment. American Psychiatric Association 2000 Annual Meeting: The Doctor-Patient Relationship: New Research Abstracts. 2000:212-213
Cummings J., Anand R., Koumaras B., Hartman R. Rivastigmine provides behavioral benefits to Alzheimer’s disease patients residing in a nursing home: findings from a 56-week trial. Neurology 2000; 54 (Suppl.3): A468-9.
Davidsson P., Blennow K., Andreasen N., et al. Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer’s disease. Neurosci Lett 2001; 300: 157-60.
Desai, A. K., Grossberg, G. T. Rivastigmine for Alzheimer's disease, Expert Rev Neurother, 2005: 5:563-80
Doraiswamy M., Anand R., Hartman R. Long-term cognitive effects in Alzheimer’s disease patients stratified by vascular risk score and treated for one year with rivastigmine. Poster presented at the 1-st International Quality Research In Dementia Conference, London, UK, 19-21 November, 2000.
Doraiswamy M., Krishnan K.R.R., Anand R., et al. Long-term effects of rivastigmine in moderately severe Alzheimer’s disease: does early initiation of therapy offer sustained benefits. In press.Prog Neuropsychopharmacol Biol Psychiatry 2002; 26 (4).
Edwards K., Goodman W., Khoury K., et al. Rapid changeover from donepezil to rivastigmine well tolerated. J Am Geriatr Soc 2001; 40: 349-504, S91 P251.
Emre M, Cummings JL, Lane RM. Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences. J Alzheimers Dis 2007; 11: 509-519.
Enz A., Amstutz R., Boddeke H. et al. Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer’s disease. In: Cuello AC, editor. Progress in Brain Research, New York: Elsevier Science Publishers, 1993. Vol. 98. p.431-8.
Etemad B. Behavioral and cognitive benefits of rivastigmine in nursing home patients with Alzheimer’s disease and related dementias: a 26-week follow-up. Int Psychogeriatr 2001; 13 (Suppl.2): 241 (Abstract P-246).
Exelon’ (Summary of Product Characteristics) East Hanover: Novartis Pharmaceuticals. Corporation, June 2001.
Farlow MR, Anand R, Messina J Jr, Hartman R, Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer’s disease. Eur Neurol. 2000;44:236-241
Farlow M., Messina J., Anand R. Long-term cognitive benefits associated with the use of rivastigmine in the treatment of Alzheimer’s disease: results following two years of treatment. Poster presented at the American Geriatric Society Annual Scientific Meeting, Nashville, USA, May 2000.
Farlow M.R., Hake A., Messina J., et al. The response of patients with Alzheimer’s disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol 2001; 58: 417-22.
Farlow, M. R. Lilly, M. L. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years, BMC Geriatr., 2005; 5:3
Farlow, M. R. Small, G. W. et al. Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysis, Dement Geriatr Cogn Disord, 2005: 192-7
Feldman HH, Lane R. Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2007; 78: 1056-1063.
Giladi N., Shabtai H., Benbunan B., et al. The effect of treatment with rivastigmine (Exelon) on cognitive functions of patients with dementia and Parkinson’s disease. Neurology 2001; 56 (Suppl.3) (Abstract P02.106).
Grace J., Daniel S., Stevens T., et al. Long-term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int Psychogeriatr 2001; 13: 199-205.
Grossberg G., Gapsar M., Touchon J., et al. Rivastigmine in Alzheimer’s disease: changes after 1 and 2 years’ treatment. Int Psychogeriatr 2001; 13 (Suppl. 2): 237 (Abstract P-328).
Grossberg G., Stahelin J., Messina J., Anand R. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Int J Geriatr Psychiatry 2000; 15: 242-7.
Inglis F. Switching acetylcholinesterase inhibitor therapy in AD. Prog Neurol Psychiatry 2001; 5: 24-5.
Jellinger R.A., Ladurner G. and Windisch (eds.) New Trends in the Diagnosis and Therapy of Alzheimer’s Disease, Springer-Verlag, Wien-New-York, 1994.
Kogan E., Henneberg A.E. Parkinson-plus-dementia-syndrome – successful treatment by rivastigmine. Poster presented at 5-th Congress of the European Society for Clinical Neuropharmacology, Opatija, Croatia, 17-21 May, 2000.
Kumar V., Anand R., Messina J., et al. An efficacy and safety analysis of Exelon in Alzheimer’s disease patients with concurrent vascular risk factors. Eur J Neurol 2000; 7: 159-69.
Lopez OL, Becker S, Wisniewski S, Saxton J, Kaufer DI, DeKosky ST. Cholinesterase inhibitor treatment alters the natural history of Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2002;72:310- 314
Marin D, Amaya K, Casciano R, et al. Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer’s disease. Int Psychogeriatr. 2003;15:385-398
Mayeux R, Sano M. Treatment of Alzheimer’s disease. N Engl J Med 1999: 1994: 34: 1670-9.
McKeith I., Del Ser T., Spano P.F., et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomized double-blind, placebo-controlled international study. Lancet 2000; 356: 2031-6.
Moretti R., Torre P., Antonello R.M., Cazzato G., Bava A. Rivastigmine is safe and effective for at least 22 months in patients with subcortical vascular dementia (VaD). In press.J Neurosci 2002; Abstract.
Moretti R., Torre P., Rodolfo M., et al. Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months’ follow-up. Eur J Neurol 2001; 8: 361-2.
Moretti R. et al. Rivastigmine in superior to aspirin plus nimodipine in subcortical vascular dementia. Poster at the 11th International conference of the ascular dementia: a comparison trial on efficacy and tolerability for 12 months’ follow-up. Eur J Neurol 2001; 8: 361-2.
Morganroth J., Graham S., Harthman R., Anand R. Electrocardiographic effects of rivastigmine. J Clin Pharmacol 2002; 42: 558-68
Nordberg A., Hellstrom-Lindahl E., Almkvist O., et al. Activity of acetylcholinesterase in CSF increases in Alzheimer’s patients after treatment with tacrine. Alzheimer’s Reports 1999; 2: 347-52.
Perry E.K., Perry R.H., Blessed G., et al. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 1978; 4: 273-7.
Potkin S.G., Anand R., Hartman R., et al. Impact of Alzheimer’s disease and rivastigmine treatment on activities on daily living over course of mild to moderately severe disease. In press. Prog Neuropsychopharmacol Biol Psychiatry 2002.
Potkin S.G., Medina J., Graham S. Safety of rivastigmine in Alzheimer я disease pooled results from phase III studies Neurobiol Aging 2000:21 :S170(Absliact770).
Reading P., Luce A., McKeith I. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001; 16: 1171-4.
Rocca W.A., Hofman A., Brayne C. // Ann. Neurol. 1991. V.30. Р.381-390
Rosler M., Anand R., Cicin-Sain A., et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomized controlled trial. BMJ 1999; 318: 633-40.
Rosler M., Retz W., Retz-Junginger P., Dennler H.J. Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer’s disease. Behav Neurol 1998; 11: 211-6.
Schneider L.S., Anand R., Farlow M.R. Systematic review of the efficacy of rivastigmine for patients with Alzheimer’s disease. Int J Geriatr Psychopharmacol 1998; 1: S26-34.
Small, G. W., Kaufer, D. et al. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years, 2005, Int J Clin Pract.: 473-7
Seltzer B. Is Long-Treatment of Alzheimer’s Disease with Cholinesterase Inhibitor Therapy Justified Drugs Aging, 2007; 24(11): 881-890
Van Laar T., de Vries J.J., Nakhosteen A., Leenders K.L. Rivastigmine is safe and effective as anti-psychotic treatment in patients with Parkinson’s disease. Poster presentation at XIV International Congress on Parkinson’s Disease (ICPD), Helsinki, Finland, 27 July-1 August 2001.
Weiser M., Rotmensch H.H., Korczyn A.D., et al. A pilot, randomized, open-label trial assessing safety and pharmacokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioural disturbances. In press.Int J Geriatr Psychiatry 2002; 17 (4).
Wesnes K.A., McKeith I.G., Ferrara R., et al. Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomized placebo-controlled international study using the Cognitive Drug Research computerized assessment system. Dement Geriatr Cogn Disord 2002; 13: 182-92.
Winblad B. et al. IDEAL. A 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease, Neurology 2007; 69 (Suppl. 1): 14-22.
Winblad B, Grossberg G, Frolich L et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007; 69: S14-22.
Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-2518.
Winblad B, Kawata AK, Beusterien KM et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry 2007; 22: 485-491.
|
